1. Introduction {#S5}
===============

India has the highest burden of tuberculosis (TB) in the world, with an estimated incidence of 2.2 million cases out of a global incidence of 9 million cases \[[@R1]\]. The prevalence of sputum smear-positive pulmonary TB is 2.27 per thousand compared to 5.05 per thousand of all forms of tuberculosis in India, and the average annual incidence of smear-positive cases is 84 per 100,000 \[[@R2]\]. HIV prevalence among incident TB patients is about 6 percent \[[@R3]\].

Through the Revised National TB Control Program (RNTCP), the Government of India provides free anti-tubercular treatment (ATT) known as Directly Observed Treatment, Short-course DOTS, a thrice weekly regimen delivered through state run and private sector providers \[[@R3]\]. Category 1 (CAT 1) DOTS is intended for new cases and consists of two months of intensive phase treatment with isoniazid (H), Rifampin (R), Pyrazinamide (Z), and Ethambutol (E), followed by four months of H and R. Category 2 (CAT 2) DOTS is for retreatment cases and has two months of HRZES (S = Streptomycin), one month of HRZE, and five months of HRE \[[@R3]\]. Patients who are adherent but do not achieve sputum smear conversion within two months following ATT initiation, require extended treatment \[[@R3]\] \[[@R4]\]. Sputum smear positivity after five months is considered to be failed treatment \[[@R3]\] \[[@R4]\]. Due to the enhanced survival benefits, it is recommended that HIV co-infected individuals receive anti-retroviral therapy (ART) regardless of CD4+ cell count soon after ATT initiation \[[@R5]\] \[[@R6]\].

Resistance to ATT has become a serious threat to TB control, with India harboring the second largest number of multi-drug resistant (resistance to H and R) TB (MDRTB) cases \[[@R7]\] \[[@R8]\]. The prevalence of MDRTB reflects the efficiency of TB management by health care providers from the public (RNTCP) and private sector as well as their collaborative efforts.

There are very few studies comparing the demographics, symptoms, DOTS uptake, side effects, and ATT adherence on pulmonary TB patients based on their HIV status \[[@R9]\] \[[@R10]\]. Also, given the slow growth of *mycobacterium* in culture (6 -- 8 weeks), challenges with tracking reports are not being readily available, and the high cost, Drug Susceptibility Testing (DST) is not a routine practice. Only a few studies have compared sputum microscopy/culture conversion as an interim indicator for final treatment outcomes in relation to HIV status \[[@R11]\]--\[[@R14]\]. Some studies have shown that HIV infection is associated with low TB bacillary density in the sputum, higher culture conversion rates and a positive association between CD4T lymphocyte count and bacillary density \[[@R13]\] \[[@R14]\]. Other studies, especially those from India, have not shown a relationship between CD4-T lymphocyte count and bacillary density \[[@R11]\] \[[@R12]\] \[[@R15]\]. This current study aims to fill this gap in the literature by first examining these factors, including drug resistance patterns, in a cohort of newly diagnosed sputum Acid Fast Bacilli (AFB) smear positive pulmonary TB patients, both with HIV co-infection, and without HIV co-infection. Our second aim is to look at differences in symptoms, ATT side effects, smear conversion rates and mortality between these groups after two months.

2. Methods {#S6}
==========

2.1. Setting and Sample {#S7}
-----------------------

Potential participants were referred to the study by staff of the pulmonary and general medicine outpatient departments, inpatient wards, the ART center, and the community HIV care center at St John\'s Medical College Hospital. These patients had clinical symptoms suggestive of pulmonary TB. Newly detected smear positive pulmonary TB patients from the referral sites and those who had definite radiological evidence of pulmonary TB pending smear results were included.

Written informed consent approved by the Institute Ethics Committee at St John\'s Medical College Hospital was obtained from all participants. For patients whose sputum tests were not already completed, researchers collected two sputum AFB smear samples, one spot and one early morning sample for testing \[[@R16]\]. Participants were considered eligible for the study if they were 18 years of age or older, willing to participate, and had one or more sputum smear samples test positive for AFB.

Participants were interviewed face-to-face for approximately one hour, and a sputum sample was tested for AFB culture and sensitivity. Those with unknown HIV status were screened for HIV infection per the National AIDS Control Organization (NACO) guidelines \[[@R17]\]. CD4 T cell counts were collected for all HIV-infected participants, if a test had not been conducted within the past month.

A one-month follow-up interview was conducted to examine improvement in symptoms, side effects and changes in ATT/ART medications, and to provide patients with AFB culture reports. Wherever possible, a two month post-intensive phase AFB smear report was collected from the RNTCP treatment cards, patient records, registers, or from the patients themselves.

Ninety-eight participants were enrolled in the study, of which three participants who were sputum smear and culture negative were removed; data of two participants whose AFB smears were negative but cultures subsequently grew *Mycobacterium Tuberculosis* were retained. Hence data analysis was done on 95 participants; 54 HIV-infected and 41-uninfected.

2.2. Measures {#S8}
-------------

### 2.2.1. Demographics {#S9}

Participant age, gender, marital status, employment, education and residence were recorded.

### 2.2.2. Symptoms and Side Effects {#S10}

At baseline, participants indicated the symptoms they had experienced from a list of common TB symptoms (e.g. cough, fever, hemoptysis). At follow-up, a list of ATT side effects (e.g., nausea, vomiting, jaundice) was added. The number of endorsed symptoms and side effects were calculated.

### 2.2.3. ATT/ART Medications {#S11}

Participants were asked about medications consumed, whether they were on DOTS, had changes to ATT/ART, where their medications were procured and who paid for their drugs. ART adherence was assessed using a Visual Analogue Scale (VAS) \[[@R18]\]. For ATT they were asked daily/weekly details of medications consumed as the drugs were recently started.

### 2.2.4. Blood, Sputum Collection and Drug Susceptibility Testing {#S12}

We collected 5 ml of blood from each HIV positive participant for CD4 count (flow cytometry) testing. HIV negative participants were screened by Enzyme linked immunosorbent assay (ELISA) \[[@R17]\]. Sputum samples from each patient were collected in sterile containers and transported to the laboratory or stored at 4°C if a delay was anticipated. The sputum smear bacillary load was graded as scanty, 1+, 2+, 3+ per WHO/RNTCP \[[@R3]\] \[[@R19]\] guidelines. Samples for culture were decontaminated and inoculated to the Mycobacterium Growth Indicator tube (Micro-MGIT) for growth and identification. DST was performed for Rifampicin (40 μg/ml), Isoniazid (1 μg/ml), Ethambutol (2 μg/ml) and Streptomycin (4 μg/ml) using lyophilized drugs (Becton Dickinson Sparks MD).

2.3. Statistical Analysis {#S13}
-------------------------

For demographic, clinical correlates and DST data, univariate descriptive statistics were calculated as appropriate. Differences between groups were analyzed by χ^2^, Fisher\'s exact test or logistic regression for categorical variables, and Mann-Whitney U-test or t-test for continuous variables, using SPSS Version 16 software. A two-tailed p-value \<0.05 was considered statistically significant.

3. Results {#S14}
==========

3.1. Demographics {#S15}
-----------------

As shown in [Table 1](#T1){ref-type="table"}, nearly three-quarters of participants were male, and a majority was Hindu, married, and had children. The median age was 35 years. HIV-infected patients were less educated (p \< 0.001) and had a lower median income than the uninfected group (Rs. 2000 vs. 4500, p = 0.012).

3.2. Clinical Correlates, DOTS Uptake and Past History of TB {#S16}
------------------------------------------------------------

As shown in [Table 2](#T2){ref-type="table"}, most patients presented with cough (96.8%), followed by fever (87.1%), weight loss (82.8%) and night sweats (77.4%). The HIV + TB group was more symptomatic than the TB only group (mean no. of symptoms 5.8 vs. 4.4, resp., p \< 0.001). Overall DOTS uptake was 74.7%, with marginally (p = 0.074) fewer participants in the HIV infected group (50%) than in the uninfected group (73.2%) on CAT1 DOTS.

Nineteen percent of HIV infected participants and 9.8% of uninfected participants were onCAT2 DOTS, and 31.5% versus 17.1%, respectively, were on other daily regimens. Nearly one in three participants in either group had a previous history for TB (p = 0.873) with 15 HIV infected participants (27.8%) and 12 uninfected participants (29.3%) having previously been treated for TB.

3.3. HIV Infection and ART {#S17}
--------------------------

The majority (n = 41/54, 76%) of the HIV infected patients reported getting tested for persistent illness, seven (13%) because their spouse tested positive, six (11.1%) on routine evaluation and one (1.9%) for high risk behavior. Twenty-one (38.9%) HIV infected participants were newly diagnosed, 24 (44.4%) were within five years (median: 1 year, IQR. 0 -- 4 yrs). Forty participants (74.1%) were on ART at baseline. The majority were on d4t (stavudine) + 3TC (lamivudine) + NVP (nevirapine) or Efavirenz (57.5 %) and 37.5% were on AZT (zidovudine) + 3TC + NVP or EFV. The median CD4+ count of the HIV-infected group was 125/μl (IQR: 82 -- 195). There was no relationship between CD4+ count and mortality or past history of TB.

3.4. Alcohol, Smoking and Co-Morbidities {#S18}
----------------------------------------

Among the men, overall 37 (52.9%) were smokers and 41 (58.6%) used alcohol with no significant difference between the groups (p = 0.417 and p = 0.617). Nine (17%) of the HIV infected participants versus eight (20%) of the uninfected patients had a history of diabetes (p = 0.720). None had a history of drug abuse.

3.5. Symptoms and Side Effects at Follow-Up {#S19}
-------------------------------------------

Comparing [Table 3](#T3){ref-type="table"} to [Table 1](#T1){ref-type="table"}, it shows that, in general, there was an improvement in symptoms at follow-up except for chest pain and hemoptysis. A comparison of the number of TB symptoms endorsed at baseline and 1 month follow-up, showed that the mean (SD) difference in symptoms endorsed in the HIV+ group was 0.63 (1.63) fewer symptoms, which was a significant decrease (p = 0.016), while the HIV− group had 0.30 (2.3) more symptoms at follow-up (p = 0.459). Perceived side effects at 1 month follow-up were significantly higher in the HIV+ group, on average, than in the HIV− group (mean 8.0 vs. 5.9, p = 0.042).

3.6. Changes in ART/ATT Medications {#S20}
-----------------------------------

Among the HIV infected group, five participants who were ART naïve \[[@R20]\] were started on triple drug regimens and there were three NRTI substitutions. Ten participants on nevirapine were substituted with efavirenz. One stopped ATT; two were substituted with fluoroquinolones and a third on RZES daily changed to CAT1 DOTS in the HIV+ group, and one participant on HRZE daily to CAT2 DOTS in the HIV− group. Eight out of the 40 participants who were on ART at baseline reported ≤80% ART adherence in the past month. As participants had just started ATT at the time of assessment, the overall adherence rates were almost 100% for ATT.

3.7. 2 Month Post-Intensive Phase Follow up and Sputum Reports {#S21}
--------------------------------------------------------------

Out of the 32 sputum smear samples available at 2 month follow up, nine (47.7%) from the HIV infected group and two (15.4%) from the -uninfected group remained positive (p = 0.13). By two months, from the data available on all the participants, eight(15.7%) of the TB+HIV group were known to be deceased, versus one (2.4%) in the TB only group, a significant difference in mortality (p = 0.04).

3.8. Resistance to ATT {#S22}
----------------------

Sputum samples were cultured for 77 participants (81%). The remaining 18 were not cultured due to technical problems (e.g. lack of sputum cups, lack of refrigeration in transport, n = 11), insufficient quantities of sputum (n = 2) and not returning for follow-up (n = 5). As shown in [Table 4](#T4){ref-type="table"}, 70.1% grew *Mycobacterium Tuberculosis*, 2.6% grew Mycobacterium other than TB, and there was no growth in the remaining 27.3%. Of the samples with available DST reports, 61.1% were resistant to Isoniazid, 31.5% to Rifampicin and MDRTB was observed in 24.5%. Eleven percent were resistant to all drugs tested (RHES). The odds of MDRTB were three times higher in the HIV-uninfected group than in the HIV group, controlling for history of TB (AOR = 3.14, 95% CI 0.74 -- 13.38). However this difference was not statistically significant (p = 0.122).

4. Discussion {#S23}
=============

To our knowledge, this is the first time that symptoms, DOTS uptake, side effects, drug adherence, resistance and mortality were studied prospectively by HIV status in a cohort of exclusively smear positive pulmonary TB patients in India. We observed that the HIV+ group was more symptomatic for TB at baseline. Their symptoms significantly improved, but they had more adverse reactions compared to the HIV-uninfected group at one month follow-up. The higher average number of symptoms in HIV+ positive patients could be due to delayed reporting to the health care provider as symptoms are attributed to HIV disease, increased prevalence of smear negative pulmonary, extra-pulmonary or disseminated forms of TB \[[@R5]\] \[[@R21]\] \[[@R22]\] and diagnostic uncertainty due to ART-related side effects or other opportunistic infections. Drug interactions, shared drug toxicities of ATT/ART, or Immune Reconstitution Inflammatory Syndrome (IRIS) could have contributed to the large number of perceived side effects in the HIV co-infected group \[[@R5]\] \[[@R21]\] \[[@R22]\].

About three quarters of our respondents were on thrice weekly DOTS regimens, with marginally (p = 0.074) fewer of the HIV infected group on CAT1. The WHO guidelines suggest that HIV patients co-infected with TB should be treated with daily regimens in the initial intensive phase \[[@R6]\] \[[@R23]\] \[[@R24]\]. A recent meta-analysis found higher rates of ATT failure, and relapses or death due to TB if the initial intensive phase was administered thrice a week instead of daily, or if ART was not initiated \[[@R25]\]. This situation could be improved by linking the RNTCP with the National AIDS Control Program \[[@R3]\] to provide and dispense daily ATT along with ART for HIV co-infected participants in their ART center.

The HIV + TB group was less literate and had a smaller median income than the HIV-group, which mirrors the socio-demographics of HIV + TB patients in the rest of the world \[[@R26]\] \[[@R27]\]. Twenty percent of our HIV positive participants were non-adherent to ART. Most studies \[[@R28]\] \[[@R29]\] report increased non-adherence in co-infected patients with better adherence to ART than to ATT \[[@R28]\]. Though there were higher numbers of HIV infected smear positives at two month follow-up, the difference was not statistically significant. A recent study on smear conversion rates had only two HIV+ patients, both continuing to remain smear positive even at the end of the fifth month of treatment \[[@R30]\].

We observed very high rates of drug resistance overall, particularly with Isoniazid, which is consistent with other studies from Karnataka \[[@R7]\] \[[@R31]\]--\[[@R33]\] and elsewhere in India \[[@R34]\] \[[@R35]\] and has implications for the rationale of the current WHO recommendation of Isoniazid prophylaxis (IPT) for latent TB in the HIV infected \[[@R36]\] \[[@R37]\]. Furthermore, substantial emerging evidence challenges the preconceived paradigm of latent/active TB disease against the backdrop of HIV infection \[[@R38]\]. As observed world-wide \[[@R12]\] \[[@R22]\]--\[[@R24]\], there was a significant difference in mortality between the HIV-infected and -uninfected group at two months follow-up.

Our study has its limitations. The small size and the regional nature of the sample may not allow generalization of results to the whole country. The low number of two month follow-up sputum smear reports may have resulted in inadequate power to find significant differences in smear conversion rates between the groups.

5. Conclusion {#S24}
=============

We found that HIVTB co-infected patients were more symptomatic at baseline. They had more perceived side effects---possibly due to shared drug toxicities of ATT/ART, drug interactions or IRIS and a higher prevalence of sputum smear positivity and mortality at follow-up, compared to HIV uninfected TB participants. There was no significant difference in drug resistance patterns between the groups, with high rates of resistance to any first line anti-tubercular drug, particularly isoniazid. Prompt initiation and daily regimens of ATT along with ART, for HIV co-infected participants from their ART center will be a step forward to meeting the WHO guideline with respect to daily ATT. The very high rate of isoniazid resistance found in this and other studies across India \[[@R23]\] \[[@R31]\]--\[[@R35]\] might preclude its use as prophylaxis for latent TB in HIV infected individuals. As resistance to ART and/or ATT is directly linked to medication non-adherence, counseling regarding adherence to both regimens, regular reinforcement on follow-up, early detection and appropriate intervention strategies to tackle non-adherence could help prevent mortality and development of resistance to ATT in the HIVTB co-infected \[[@R39]\] \[[@R40]\].
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###### 

Demographic characteristics of the sample.

                                    All      HIV + TB       TB only                                          
  --------------------------------- -------- -------------- --------- -------------- -------- -------------- -------
  Gender                                                                                                     0.521
  Male                              70       73.7           41        75.9           29       70.7           
  Female                            24       25.3           12        22.2           12       29.3           
  Hijra                             1        1.1            1         1.9            0        0.0            
  Place of residence                                                                                         0.304
  Bangalore                         41       43.2           30        55.6           22       53.7           
  Other Karnataka                   32       33.7           18        33.3           10       24.4           
  Other state                       22       23.2           6         11.1           9        22.0           
  Education                                                                                                  0.000
  None                              19       20.0           12        22.2           7        17.1           
  \<4 years                         18       18.9           17        31.5           1        2.4            
  4 -- 9 years                      23       24.2           6         11.1           17       41.5           
  ≥10 years                         35       36.8           19        35.2           16       39.0           
  Marital status                                                                                             0.639
  Married                           73       76.8           42        77.8           31       75.6           
  Single                            18       18.9           9         16.7           9        22.0           
  Widowed                           4        4.2            3         5.6            1        2.4            
  Lives alone                       18       18.9           14        25.9           4        9.8            0.046
  Has children                      63       66.3           38        70.4           25       61.0           0.337
  Hindu                             81       85.3           50        92.6           31       75.6           0.021
                                    median   IQR            median    IQR            median   IQR            
  Age, years                        35       30 -- 43       35        32 -- 41       35       25 -- 53       0.889
  Income, Rupees (if any, n = 85)   3000     1000 -- 5000   2000      1000 -- 4625   4500     1500 -- 6000   0.012

Difference between groups tested via chi-square test for categorical variables and Mann-Whitney U test for continuous variables.

###### 

TB related variables.

                                              Available   All   HIV + TB   TB only   p-value^[a](#TFN2){ref-type="table-fn"}^                 
  ------------------------------------------- ----------- ----- ---------- --------- ------------------------------------------ ----- ------- -------
  History of TB                               95          27    28.4       15        27.8                                       12    29.3    0.873
  TB symptoms:                                93                                                                                              
  Cough                                                   90    96.8       51        92.2                                       39    97.5    0.731
  Fever                                                   81    87.1       51        96.2                                       30    75.0    0.003
  Night sweats                                            72    77.4       45        84.9                                       27    67.5    0.047
  Shortness of breath                                     69    74.2       46        86.8                                       23    57.5    0.001
  Chest pain                                              59    63.4       43        81.1                                       16    40.0    0.000
  Blood in sputum                                         34    36.6       24        45.3                                       10    25.0    0.044
  Weight loss                                             77    82.8       47        88.7                                       30    75.0    0.084
  Symptoms, mean (SD)                                     5.2   (1.4)      5.8       (1.3)                                      4.4   (1.2)   0.000
  TB regimen                                  95                                                                                              0.074
  DOTS cat 1                                              57    60.0       27        50.0                                       30    73.2    
  DOTS cat 2                                              14    14.7       10        18.5                                       4     9.8     
  Other                                                   24    25.3       17        31.5                                       7     17.1    
  Sputum AFB at baseline                      95                                                                                              0.638
  Negative^[b](#TFN3){ref-type="table-fn"}^               2     2.1        1         1.9                                        1     2.4     
  Scanty                                                  13    13.7       5         9.3                                        8     19.5    
  1+                                                      39    41.1       24        44.4                                       15    36.6    
  2+                                                      22    23.2       12        22.2                                       10    24.4    
  3+                                                      19    20.0       12        22.2                                       7     17.1    
  2 mo. FU sputum smear positive              32          11    34.4       9         47.7                                       2     15.4    0.128

Difference between groups tested via chi-square test for categorical variables, and t-test for continuous variables;

These patients grew *Mycobacterium Tuberculosis* in culture.

###### 

Side effects of TB Treatment after 1 month.

                                           All (n = 78)   HIV + TB (n = 44)   TB only (n = 34)                         
  ---------------------------------------- -------------- ------------------- ------------------ ------- ----- ------- -------
  Symptoms:                                                                                                            
  Fever                                    63             80.8                37                 84.1    26    76.5    0.563
  Night sweats                             51             65.4                25                 56.8    26    76.5    0.094
  Persistent cough                         68             87.2                40                 90.9    28    82.4    0.317
  Expectoration                            54             69.2                28                 63.6    26    76.5    0.323
  Blood in sputum                          37             47.4                22                 50.0    15    44.1    0.653
  Difficulty breathing                     49             62.8                30                 68.2    19    55.9    0.346
  Chest pain                               52             66.7                35                 79.5    17    50.0    0.008
  Perceived side effects                                                                                               
  Jaundice                                 43             55.1                28                 63.6    15    44.1    0.110
  Skin rash                                48             61.5                30                 68.2    18    52.9    0.241
  Tingling/numb fingers/toes               33             42.3                25                 56.8    8     23.5    0.005
  Nausea/vomiting                          42             53.8                25                 56.8    17    50.0    0.648
  Stomach pain/cramps                      44             56.4                28                 63.6    16    47.1    0.171
  Giddy/loss of balance                    46             59.0                28                 63.6    18    52.9    0.363
  Decreased urine output                   30             38.5                18                 40.9    12    35.3    0.646
  Joint pain                               42             53.8                27                 61.4    15    44.1    0.171
  Headache                                 47             60.3                27                 61.4    20    58.5    1.000
  Swelling in feet                         30             38.5                21                 47.7    9     26.5    0.065
  Swelling neck/groin/axilla               27             34.6                20                 45.5    7     20.6    0.031
  Difficulty seeing                        24             30.8                17                 38.6    7     20.6    0.137
  Difficulty hearing                       16             20.5                10                 22.7    6     17.6    0.778
  Weakness in limbs                        23             29.5                17                 38.6    6     17.6    0.050
  Other                                    3              3.8                 2                  4.5     1     2.9     1.000
  Total no. symptoms endorsed: mean (SD)   6.4            (4.4)               7.3                (4.3)   5.1   (4.4)   0.029

Based on Fisher\'s exact test for frequencies and on t-test for mean.

###### 

Resistance testing results.

                      All         HIV + TB   TB only                             
  ------------------- ----------- ---------- ---------- ------ ---------- ------ -------
  Cultured samples:   (n = 77)               (n = 40)          (n = 37)          0.284
   No growth          21          27.3       14         35.0   7          18.9   
   MOTT               2           2.6        1          2.5    1          2.7    
   M-TB               54          70.1       25         62.5   29         78.4   
  Resistant to:       (n = 54):              (n = 25)          (n = 29)          
   Rifampicin (R)     17          31.5       7          28.0   10         34.5   0.770
   Isoniazid (H)      33          61.1       14         56.0   19         65.5   0.579
   Streptomycin (S)   15          27.8       7          28.0   8          27.6   1.000
   Ethambutol (E)     20          37.0       10         40.0   10         34.5   0.780
   H + R (=MDR)       13          24.1       4          16.0   9          31.0   0.223
   H+R+S+E            6           11.1       2          8.0    4          13.8   0.675
   Any drug           40          74.1       19         76.0   21         72.4   1.000

MDR, multi-drug resistance; MOTT, *Mycobacterium other than TB; M-TB, Mycobacterium Tuberculosis;*

on Fisher\'s exact test for frequencies.
